Moroxite is led by experienced serial entrepreneurs and researchers with extensive competence in research, development and commercialisation of innovative medical solutions.
Moroxite AB is a medical research company committed to developing innovative solutions for diseases with large unmet medical human needs and making a lasting societal contribution.
We develop IP protected drug candidates up to early proof of concept. Our primary target is to spin out candidates to major global med tech and pharmaceutical companies through license, milestone or royalty agreements.
The company was founded in 2020 by Professor Lars Lidgren, Professor Magnus Tägil and PhD Deepak Raina with a vision to develop a novel drug delivery systems based on bio-modulation platforms and drugs binding to nano and micro apatite particles.
Board of Moroxite AB
Rülf has a MA in Economics and extensive experience in the med-tech and IT industry. He has worked at the Swedish Chamber of Commerce, IFÖ, Facit - Eriksson Information and was the CEO of Axis Communications. He started ProstaLund and has been regional director at VisitSweden. Currently a board member of Safeture, Bibbinstruments, Curando Nordic and Senior Advisor in Igelösa Life Science.
Lidgren has a BA in Social Science in addition to studies in Business Administration, Media Science and English language at Lund university and comparative social work at University of Portsmouth, England. She has prior experience as a coordinator in the private and public sector and has most recently worked with business development, communication, regulatory issues and project management with IT and corporate health profile in listed companies.
Kaul, has a master’s degree with specialization in marketing from University of Mumbai, India and has over eight years of experience within marketing, talent, client servicing, business development. Her last position was as a General Manager, Marketing in a sports management company based in India and as a senior project manager for a non-profit organization.